These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38947323)

  • 1. New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.
    Torkildsen CF; Austdal M; Jarmund AH; Kleinmanns K; Lamark EK; Nilsen EB; Stefansson I; Sande RK; Iversen AC; Thomsen LCV; Bjørge L
    Front Immunol; 2024; 15():1394497. PubMed ID: 38947323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer.
    Uehara T; Matsuzaki J; Yoshida H; Ogawa Y; Miura J; Fujimiya H; Yamamoto Y; Kawauchi J; Takizawa S; Yonemori K; Sakamoto H; Kato K; Ishikawa M; Ochiya T
    Jpn J Clin Oncol; 2024 Aug; 54(8):917-925. PubMed ID: 38651188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with
    Kim SR; Parbhakar A; Li X; Bernardini MQ; Hogen L; May T
    Int J Gynecol Cancer; 2024 Jun; 34(6):879-885. PubMed ID: 38548312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of Paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients - interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial).
    Wang Q; Liu H; Shen Y; Shen L; Li J; Feng W
    J Ovarian Res; 2024 Jul; 17(1):145. PubMed ID: 38997720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
    Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
    J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
    Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
    Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
    van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
    Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction.
    De Jong D; Otify M; Chen I; Jackson D; Jayasinghe K; Nugent D; Thangavelu A; Theophilou G; Laios A
    Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
    Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
    Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
    Takaya H; Nakai H; Sakai K; Nishio K; Murakami K; Mandai M; Matsumura N
    Gynecol Oncol; 2020 Feb; 156(2):415-422. PubMed ID: 31785864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
    AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
    Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer.
    McAdams J; Ebott J; Jansen C; Kim C; Maiz D; Ou J; Hanley LC; Cruz P; James NE
    J Ovarian Res; 2024 Sep; 17(1):192. PubMed ID: 39342316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
    Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
    J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
    Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
    Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.